Neuralgia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for neuralgia. 6 active patents protecting 2 drugs from 2+ originators. First major cliff: 2028. Daily refresh.

2
Approved drugs
6
Active US patents
62/100
Avg vulnerability
—
Annual revenue covered

Originators in Neuralgia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Fresenius Kabi 4 patents Averitas 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating neuralgia. Each bar = one year. Y-axis scaled to peak year (2 patents).

1
26
1
28
1
29
1
30
2
35

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lignospan Forte
Lidocaine Hydrochloride
 Fresenius Kabi 4 71 — 2026-07-24
Qutenza
CAPSAICIN
 Averitas 2 52 — 2028-12-15

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8759401 Lignospan Forte method of use 85 2026-07-24
8540665 Lignospan Forte method of use 73 2029-10-22
9358338 Lignospan Forte method of use 62 2035-04-27
9370622 Lignospan Forte method of use 62 2035-09-28
9226903 Qutenza formulation 55 2028-12-15
8821920 Qutenza formulation 48 2030-03-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8821920 Qutenza formulation 48 2030-03-26
9226903 Qutenza formulation 55 2028-12-15
9370622 Lignospan Forte method of use 62 2035-09-28
9358338 Lignospan Forte method of use 62 2035-04-27
8540665 Lignospan Forte method of use 73 2029-10-22
8759401 Lignospan Forte method of use 85 2026-07-24

Related